Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Galcanezumab was found to significantly improve work productivity and reduce interictal burden in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.
In CONQUER, the safety and efficacy of galcanezumab, a calcitonin gene-related peptide (CGRP) antagonist, was evaluated in patients with episodic (n=269) or chronic migraine (n=193) with documented treatment failure on 2 to 4 different standard of care migraine preventive medications. Patients were randomized to receive galcanezumab 120mg per month (with a 240mg loading dose) or placebo for 3 months.
The study met its primary end point demonstrating a greater overall mean change from baseline in the number of monthly migraine headache days with galcanezumab. An analysis of secondary end points showed statistically significant improvements in work productivity and reductions in overall work productivity loss, as measured by the migraine-specific Work Productivity and Activity Impairment Questionnaire, in patients treated with galcanezumab compared with those who received placebo (-14.3% vs -3.5%; P <.01). Moreover, non-work-related activity impairment was also statistically significantly reduced with galcanezumab compared with placebo (-20.7% vs -8.6%; P <.01).
As for patient well-being between migraine attacks, the average change in the 4-item Migraine Interictal Burden Scale was found to be statistically significantly greater in patients who received galcanezumab vs those who received placebo (-1.8 vs -0.8, respectively; P <.0001).
“Migraine imposes a profoundly debilitating burden, including interference with work and compromises to social life, that extends beyond the duration of the attacks themselves,” said Gudarz Davar, MD, vice president, neurology development, Lilly Bio-Medicines. “In this important analysis of the clinical trial data, patients reported that Emgality improved their day-to-day functioning and work productivity.”
Emgality (Lilly) is currently approved for the preventive treatment of migraine in adults and for the treatment of episodic cluster headache.
For more information visit lilly.com.
